These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 31948539)

  • 41. Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC).
    McCarthy F; Roshani R; Steele J; Hagemann T
    J Leukoc Biol; 2013 Dec; 94(6):1201-6. PubMed ID: 23695306
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Updates on immunotherapy in non-small cell lung cancer.
    Shimanovsky A; Dasanu CA
    Expert Opin Biol Ther; 2014 Apr; 14(4):411-8. PubMed ID: 24512518
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.
    Socinski MA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469
    [No Abstract]   [Full Text] [Related]  

  • 44. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
    Anagnostou VK; Brahmer JR
    Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer.
    Daly ME; Monjazeb AM; Kelly K
    J Thorac Oncol; 2015 Dec; 10(12):1685-93. PubMed ID: 26484629
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenic targets in non-small cell lung cancer: more is more.
    Gnjatic S
    Clin Cancer Res; 2005 Aug; 11(15):5331-2. PubMed ID: 16061843
    [No Abstract]   [Full Text] [Related]  

  • 47. Immunotherapy for non-small-cell lung cancer.
    Thomas A; Jakopovic M
    Expert Opin Biol Ther; 2014 Aug; 14(8):1061-4. PubMed ID: 24878420
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy?
    Cetin B; Bilgetekin İ; Ozet A
    Curr Probl Cancer; 2019 Feb; 43(1):43-53. PubMed ID: 30104030
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monitoring immunotherapy outcomes with circulating tumor DNA.
    Goldberg SB; Patel AA
    Immunotherapy; 2018 Sep; 10(12):1023-1025. PubMed ID: 30185140
    [No Abstract]   [Full Text] [Related]  

  • 50. Immune modulation as a therapeutic strategy for non-small-cell lung cancer.
    Holt GE; Disis ML
    Clin Lung Cancer; 2008 Feb; 9 Suppl 1():S13-9. PubMed ID: 18540530
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted Therapy and Immunotherapy for Lung Cancer.
    Naylor EC; Desani JK; Chung PK
    Surg Oncol Clin N Am; 2016 Jul; 25(3):601-9. PubMed ID: 27261918
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The role of immune checkpoint inhibitors in lung cancer: from clinical trials to clinical practice].
    Wang ZM; Song Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):95-99. PubMed ID: 32062879
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Meta-Analysis of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer.
    Cao C; Le A; Bott M; Yang CJ; Gossot D; Melfi F; Tian DH; Guo A
    Curr Oncol; 2021 Nov; 28(6):4686-4701. PubMed ID: 34898553
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
    Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pneumonectomy: calculable or non-tolerable risk factor in trimodal therapy for Stage III non-small-cell lung cancer?
    Steger V; Spengler W; Hetzel J; Veit S; Walker T; Mustafi M; Friedel G; Walles T
    Eur J Cardiothorac Surg; 2012 Apr; 41(4):880-5; discussion 885. PubMed ID: 22233799
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.
    Steendam CM; Dammeijer F; Aerts JGJV; Cornelissen R
    Immunotherapy; 2017 May; 9(6):507-520. PubMed ID: 28472903
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gene immunotherapy for non-small cell lung cancer.
    Nemunaitis JJ
    Methods Mol Biol; 2009; 542():499-514. PubMed ID: 19565919
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Moving Immunotherapy Into Early-Stage Lung Cancer.
    Linehan A; Forde PM
    Cancer J; 2020; 26(6):543-547. PubMed ID: 33298726
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome].
    Shepherd FA; Douillard JY; Blumenschein GR
    Zhongguo Fei Ai Za Zhi; 2013 Apr; 16(4):C9-20. PubMed ID: 23601304
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?
    Waqar SN; Morgensztern D
    Expert Rev Clin Immunol; 2015; 11(8):871-3. PubMed ID: 26051156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.